Department of Clinical Laboratory, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
School of Basic Medical Science, Fujian Medical University, Fuzhou, China.
BMC Pregnancy Childbirth. 2023 Mar 27;23(1):207. doi: 10.1186/s12884-023-05478-9.
BACKGROUND: Group B Streptococcus (GBS), also referred as Streptococcus agalactiae, is one of the leading causes of life-threatening invasive diseases such as bacteremia, meningitis, pneumonia and urinary tract infection in pregnant women and neonates. Rates of GBS colonization vary by regions, but large-sample studies on maternal GBS status are limited in southern China. As a result, the prevalence of GBS among pregnant women and its associated risk factors and the efficacy of intrapartum antibiotic prophylaxis (IAP) intervention in preventing adverse pregnancy and neonatal outcomes remain poorly understood in southern China. METHODS: To fill this gap, we retrospectively analyzed demographic and obstetrical data of pregnant women who have undergone GBS screening and delivered between 2016 and 2018 in Xiamen, China. A total of 43,822 pregnant women were enrolled and only a few GBS-positive women did not receive IAP administration. Possible risk factors for GBS colonization were assayed by univariate and multivariate logistic regression analysis. Generalized linear regression model was applicated to analyze whether IAP is one of the impact factors of the hospital length of stay of the target women. RESULTS: The overall GBS colonization rate was 13.47% (5902/43,822). Although women > 35 years old (P = 0.0363) and women with diabetes mellitus (DM, P = 0.001) had a higher prevalence of GBS colonization, the interaction between ages and GBS colonization was not statistically significant in Logistic Regression analysis (adjusted OR = 1.0014; 95% CI, 0.9950, 1.0077). The rate of multiple births was significantly dropped in GBS-positive group than that of GBS-negative group (P = 0.0145), with no significant difference in the rate of fetal reduction (P = 0.3304). Additionally, the modes of delivery and the incidences of abortion, premature delivery, premature rupture of membranes, abnormal amniotic fluid and puerperal infection were not significantly different between the two groups. The hospitalization stays of the subjects were not influenced by GBS infection. As for neonatal outcomes, the cases of fetal death in maternal GBS-positive group did not statistically differ from that in maternal GBS-negative group. CONCLUSION: Our data identified that pregnant women with DM are at high risk of GBS infection and IAP is highly effective in prevention of adverse pregnancy and neonatal outcomes. This stressed the necessity of universal screening of maternal GBS status and IAP administration to the target population in China, and women with DM should be considered as priorities.
背景:B 群链球菌(GBS),又称无乳链球菌,是导致孕妇和新生儿致命性侵袭性疾病(如菌血症、脑膜炎、肺炎和尿路感染)的主要原因之一。GBS 定植率因地区而异,但中国南方地区缺乏关于母体 GBS 状况的大样本研究。因此,中国南方地区孕妇 GBS 感染的流行率及其相关危险因素,以及产时抗生素预防(IAP)干预预防不良妊娠和新生儿结局的效果仍知之甚少。
方法:为了填补这一空白,我们回顾性分析了 2016 年至 2018 年在中国厦门进行 GBS 筛查和分娩的孕妇的人口统计学和产科数据。共纳入 43822 名孕妇,只有少数 GBS 阳性孕妇未接受 IAP 治疗。采用单因素和多因素 logistic 回归分析检测 GBS 定植的可能危险因素。应用广义线性回归模型分析 IAP 是否是目标妇女住院时间的影响因素之一。
结果:总的 GBS 定植率为 13.47%(5902/43822)。尽管年龄>35 岁的孕妇(P=0.0363)和患有糖尿病(DM)的孕妇(P=0.001)的 GBS 定植率更高,但 logistic 回归分析中年龄与 GBS 定植之间的交互作用无统计学意义(调整后的 OR=1.0014;95%CI,0.9950,1.0077)。GBS 阳性组的多胎率明显低于 GBS 阴性组(P=0.0145),而胎儿减少率无显著差异(P=0.3304)。此外,两组间分娩方式、流产率、早产率、胎膜早破率、羊水异常和产褥感染率无显著差异。母体 GBS 感染不影响住院时间。对于新生儿结局,母体 GBS 阳性组的胎儿死亡病例与母体 GBS 阴性组无统计学差异。
结论:我们的数据表明,患有糖尿病的孕妇 GBS 感染风险较高,IAP 对预防不良妊娠和新生儿结局非常有效。这强调了在中国对目标人群进行母体 GBS 状况筛查和 IAP 管理的必要性,应优先考虑患有糖尿病的妇女。
Zhongguo Dang Dai Er Ke Za Zhi.
J Microbiol Immunol Infect. 2017-8-23
Ginekol Pol. 2014-6
Zhonghua Fu Chan Ke Za Zhi. 2019-3-25
Cochrane Database Syst Rev. 2013-1-31
BMJ Public Health. 2025-7-23
BMC Pregnancy Childbirth. 2025-4-12
BMC Infect Dis. 2025-1-21
Microorganisms. 2021-12-13
Eur J Obstet Gynecol Reprod Biol. 2021-12
Emerg Infect Dis. 2019-11
Braz J Microbiol. 2019-8-20
Eur J Obstet Gynecol Reprod Biol. 2019-7-2
Microbiol Spectr. 2019-3